Predictive Genetic Testing: Technology Landscape
The Improved Accuracy and Clinical Utility of PGTs Will Enable the Seamless Adoption of Precision Medicine.
21-Jul-2022
Global
Technology Research
DA51-01-00-00-00
HC03566-GL-TR_26739
Predictive genetic testing refers to the testing of genetic mutations and variations in an individual to predict the risk of disease susceptibility and the inheritance of Mendelian diseases and other complex diseases. Genomic analysis studies such as genome-wide association studies (GWAS), SNP arrays, and the WGS of select populations have helped to understand the impact of mutations and variants on health and disease risk; rising awareness and public/private initiatives for preventive healthcare are also driving market growth. Massively parallel NGS-based methods and advanced genomic and cytogenomic analysis tools are used in predictive genetic tests (PGTs) to analyze gene mutations, variants, and chromosomal aberrations, which can increase the susceptibility of a disease; PGTs are also being used to predict disease severity.
The use of large-scale genomics data to develop population-based genomic studies for predictive and preventive health is also gaining traction, and several countries, including the United States and the United Kingdom, have carried out large-scale genomic studies to develop DNA repositories that can be used in preventative healthcare strategies. The key technologies used in genomic analysis include whole genome sequencing (WGS), whole exome sequencing (WES), targeted sequencing (gene panels), and genotyping (SNP arrays, optical genome mapping), and each technology has its own advantages and disadvantages. Combining DNA analysis with microbiome DNA assessment and RNA analysis can improve the clinical utility of PGTs, and many research organizations and start-ups are focusing on combination-based tests to improve clinical utility for disease risk prediction.
Although PGTs have been commercialized for more than 10 years, adoption continues to remain low. This is primarily due to the unclear clinical benefits of these genetic tests and the lack of involvement of health authorities and regulatory body oversight. The most widely used PGT for clinical purposes is hereditary cancer testing (HCT), where a multitude of genes are analyzed for inheritable cancer prediction. While BRCA1 and BRAC2 mutation testing has been used for breast cancer and ovarian cancer risk prediction, the discovery of new gene markers, variant interpretation tools, and the development of multiplexed assays of multigene panels will make this testing type more clinically relevant. The widespread utilization of PGTs can also foster an era of personalized medicine based on individual disease risk profiles.
PGTs are also being increasingly developed for nonclinical purposes, and they are widely available in the direct-to-consumer (DTC) format where individual genomes are assessed to predict innate traits and improve overall health and wellness.
This Frost & Sullivan research service discusses the importance of predictive genetic testing in disease susceptibility prediction, the discovery of novel disease biomarkers for drug discovery, pharmacogenomics, metabolism, nutrigenomic profiling, and well-being, among other topics.
Several new companies have entered this market, and they are focused on reducing test costs and improving test sensitivity and accuracy. Collaborations are also on the rise, with pharmaceutical companies partnering with PGT developers and public healthcare systems engaging with multiple entities to work on genomic analysis to accelerate preventive health strategies at a national level. The deployment of advanced data analysis tools and data storage and management systems is also fostering the growth of PGTs.
Why is it Increasingly Difficult to Grow?The Strategic Imperative 8™: Factors Creating Pressure on Growth
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Predictive Genetic Testing Industry
Growth Opportunities Fuel the Growth Pipeline Engine™
Research Methodology
Research Context and Scope
Key Questions The Study Will Answer
Predictive Genetic Tests
Utility of PGT across a Spectrum of Health Applications
What Drives the Adoption of Predictive Genetic Testing?
What Drives the Adoption of Predictive Genetic Testing? (continued)
A Lack of Clinical Validation alongside Fuzzy Reimbursement Policies and an Ill-defined Regulatory Landscape are Deterrents.
Evolving Landscape with a Growing Number of Industry Partnerships, Rising Investments, and Technology Advancements
Approaches Deployed in Predictive Genetic Testing
Rising Adoption of WGS in Predictive Genetic Testing
WES is a Comprehensive, Relatively Low-cost Approach for PGT.
Targeted Sequencing is Most Commonly Used for Hereditary Cancer Prediction.
SNP Microarray-based Genotyping is Mainly Used in DTC PGT.
Emerging Technologies for Predictive Genetic Testing
Comparison of Approaches for Predictive Genetic Testing
Emerging Areas of R&D to Improve PGT
Key Stakeholders are Leveraging/Developing Digital Tools for Genomic Data Analysis and Management.
Predictive Genetic Tests Deployed across Disease Areas
Application in Cancer Predictive Testing
Application in Cardiovascular Predictive Testing
Acquisitions are Paving the Way to Accelerate Developments and Expand Footprint.
Strategic Collaboration to Advance PGT
Public Initiatives Driving the Adoption of PGT
Recent Funding Activity
Recent Funding Activity (continued)
Growth Opportunity 1: Blockchain-based Decentralized Genomic Data Sharing
Growth Opportunity 1: Blockchain-based Decentralized Genomic Data Sharing (continued)
Growth Opportunity 2: Large-scale Population-level Genomic Studies In Emerging Nations
Growth Opportunity 2: Large-scale Population-level Genomic Studies In Emerging Nations (continued)
Growth Opportunity 3: Development of Advanced Variant Analysis Tools
Growth Opportunity 3: Development of Advanced Variant Analysis Tools (continued)
Growth Opportunity 4: Collaboration among Healthcare Systems, Pharma Companies, and Tech Developers
Growth Opportunity 4: Collaboration among Healthcare Systems, Pharma Companies, and Tech Developers (continued)
Your Next Steps
Why Frost, Why Now?
Legal Disclaimer
Speak directly with our analytics experts for tailored recommendations.
Recent related Healthcare research
16 Nov 2026 | North America | Frost Radar
Frost Radar™: Healthcare Data Interoperability Platforms and Integration Engines in North America, 2026
This Frost Radar™ analyzes the healthcare data platform and integration engine vendors that enable healthcare organization to improve the exchange, utilization, contextualization, and management of clinical, operational, financial, and administrative data. Data issues, AI adoption, and solution gove...
03 Nov 2026 | North America | Market Research
Enterprise Imaging Market, United States, 2025–2030
Enterprise imaging is no longer a technology upgrade. It is becoming the operating model for imaging across the provider organization, and the next investment cycle will decide which vendors lead it. This study gives vendors, ecosystem partners, and provider leaders a 360-degree view of that shift, ...
02 Nov 2026 | Global | Market Research
Continuous Glucose Monitoring Market, Global, 2026
The global continuous glucose monitoring (CGM) market is undergoing a fundamental transformation as the technology evolves from a prescription-led glucose monitoring device into an AI-connected metabolic intelligence ecosystem. Market expansion is increasingly driven by the emergence of over-the-cou...
28 Oct 2026 | Global | Frost Radar
Frost Radar™: Health Monitoring Wearable Solutions, 2026
The health monitoring wearables industry is undergoing a profound transformation as competitive advantage shifts from device hardware to integrated digital health ecosystems. Market leaders are differentiating through clinically validated health insights, longitudinal data platforms, AI-enabled anal...
26 Oct 2026 | Global | Technology Research
Game-Changing Innovations Transforming Cardiovascular Care
The study analyzes game-changing technologies transforming cardiovascular care across diagnosis, image-guided intervention, functional assessment, clinical workflow, and longitudinal patient monitoring. The analysis covers five segments: diagnostic imaging and AI-enabled cardiac assessment; interve...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.